Real Clinical Effectiveness of Molnupiravir Against 30-day
Mortality Among 74 541 SARS-CoV-2-Positive Patients: A
Nationwide Cohort Study From the Czech Republic

ENPřihlásit se Přihlásit se (EduID)

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 ...

Přehled o publikaci

J 2024

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

PAVLÍK, Tomáš, Jiří JARKOVSKÝ, Ondřej ŠANCA, Martina KOZIAR VASAKOVA, Pavel DLOUHY et. al.

Základní údaje

Originální název

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

Autoři

PAVLÍK, Tomáš, Jiří JARKOVSKÝ, Ondřej ŠANCA, Martina KOZIAR VASAKOVA, Pavel DLOUHY, Vladimir CERNY, Petr ŠTOURAČ, Vlastimil VÁLEK a Ladislav DUŠEK

Vydání

OPEN FORUM INFECTIOUS DISEASES, CARY, OXFORD UNIV PRESS INC, 2024, 2328-8957

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Organizace

Lékařská fakulta – Masarykova univerzita – Repozitář

DOI

http://dx.doi.org/10.1093/ofid/ofae685

UT WoS

001374759800001

EID Scopus

2-s2.0-85212131397

Klíčová slova anglicky

30-day all-cause mortality; COVID-19; COVID-19-related mortality; molnupiravir; SARS-CoV-2 infection

Návaznosti

LX22NPO5101, projekt VaV.

Změněno: 7. 2. 2025 00:50, RNDr. Daniel Jakubík

Anotace

V originále

lt; .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. Conclusions. In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.

Přiložené soubory

https://is.muni.cz/publication/2475062/Real_Clinical_Effectiveness_of_Molnupiravir_Against_30-day_Mortality_Among_74_541_SARS-CoV-2-Positive_Patients_A_Nationwide_Cohort_Study_From_the_Czech_Republic.pdf

Citovat

PAVLÍK, Tomáš, Jiří JARKOVSKÝ, Ondřej ŠANCA, Martina KOZIAR VASAKOVA, Pavel DLOUHY, Vladimir CERNY, Petr ŠTOURAČ, Vlastimil VÁLEK a Ladislav DUŠEK. Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic. OPEN FORUM INFECTIOUS DISEASES. CARY: OXFORD UNIV PRESS INC, 2024, roč. 11, č. 12, s. 1-10. ISSN 2328-8957. Dostupné z: https://dx.doi.org/10.1093/ofid/ofae685.

@article{67808,
   author = {Pavlík, Tomáš and Jarkovský, Jiří and Šanca, Ondřej and Koziar Vasakova, Martina and Dlouhy, Pavel and Cerny, Vladimir and Štourač, Petr and Válek, Vlastimil and Dušek, Ladislav},
   article_location = {CARY},
   article_number = {12},
   doi = {http://dx.doi.org/10.1093/ofid/ofae685},
   keywords = {30-day all-cause mortality; COVID-19; COVID-19-related mortality; molnupiravir; SARS-CoV-2 infection},
   language = {eng},
   issn = {2328-8957},
   journal = {OPEN FORUM INFECTIOUS DISEASES},
   title = {Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic},
   url = {https://academic.oup.com/ofid/article/11/12/ofae685/7904736?login=true},
   volume = {11},
   year = {2024}
}

TY  - JOUR
ID  - 67808
AU  - Pavlík, Tomáš - Jarkovský, Jiří - Šanca, Ondřej - Koziar Vasakova, Martina - Dlouhy, Pavel - Cerny, Vladimir - Štourač, Petr - Válek, Vlastimil - Dušek, Ladislav
PY  - 2024
TI  - Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic
JF  - OPEN FORUM INFECTIOUS DISEASES
VL  - 11
IS  - 12
SP  - 1-10
EP  - 1-10
PB  - OXFORD UNIV PRESS INC
SN  - 2328-8957
KW  - 30-day all-cause mortality
KW  - COVID-19
KW  - COVID-19-related mortality
KW  - molnupiravir
KW  - SARS-CoV-2 infection
UR  - https://academic.oup.com/ofid/article/11/12/ofae685/7904736?login=true
N2  - lt; .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. Conclusions. In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.
ER  -

PAVLÍK, Tomáš, Jiří JARKOVSKÝ, Ondřej ŠANCA, Martina KOZIAR VASAKOVA, Pavel DLOUHY, Vladimir CERNY, Petr ŠTOURAČ, Vlastimil VÁLEK a Ladislav DUŠEK. Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic. \textit{OPEN FORUM INFECTIOUS DISEASES}. CARY: OXFORD UNIV PRESS INC, 2024, roč.~11, č.~12, s.~1-10. ISSN~2328-8957. Dostupné z: https://dx.doi.org/10.1093/ofid/ofae685.